Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CT-P59

Understanding COVID-19 and varying responses across the globe

At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global...

Blue Latitude Health

- PMLiVE

Moderna’s COVID-19 vaccine enters pivotal phase 3 trial

Large-scale study will evaluate vaccine in 30,000 participants

- PMLiVE

Pfizer, BioNTech identify and advance lead COVID-19 vaccine candidate

Companies pick the most promising candidate to take into phase 2/3

AstraZeneca AZ

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Follows initial deal agreed in June

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

Why pharma must trust the science of behaviour

With behaviour being the best weapon we currently have to combat coronavirus, Chris Ross explores why the application of behavioural science will be key to better health far beyond COVID-19

- PMLiVE

US government pays $1.95bn for Pfizer/BioNTech’s COVID-19 vaccine

Initial order includes 100 million doses

- PMLiVE

RedHill Biopharma advances phase 2/3 COVID-19 programme

Submits clinical trial applications in Mexico and Brazil

- PMLiVE

EMA to support real-world monitoring of COVID-19 treatments/vaccines

New infrastructure will support real-world studies

- PMLiVE

China’s CanSino Biologics reveals phase 2 coronavirus vaccine results

Candidate induced neutralising antibody responses

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

AstraZeneca AZ

AZ/Oxford’s COVID-19 vaccine proves promising in early trials

Vaccine candidate produced robust immune response

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links